AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04542122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choices and judgements
Description: In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
Study NCT05106348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aerobic Fitness Test
Description: aerobic fitness test to assess wheelchair rugby players capacity
Study NCT01740687 — intervention group
Intervention type: DEVICE
Intervention: ESS305 (Essure, BAY1454032)
Description: Essure Permanent Birth Control
Study NCT01740687 — intervention group
Intervention type: PROCEDURE
Intervention: NovaSure
Description: Nova Sure Endometrial Ablation
Study NCT06058962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suramin Sodium
Description: Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
Study NCT06058962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin Sodium
Description: Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT02805452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinate of Solifenacin
Study NCT02805452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Succinate of Solifenacin
Study NCT01906268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment (ABMT) - Active
Description: The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
Study NCT01906268 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attentional Bias Modification Treatment - Placebo
Description: The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
Study NCT03478670 — intervention group
Intervention type: GENETIC
Intervention: Strimvelis
Description: Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273.
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Administered orally once a day
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ezetimibe
Description: Administered orally once a day
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day
Study NCT03250143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine vs azathioprine
Description: Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
Study NCT02392988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture treatment
Description: acupuncture treatment
Study NCT02392988 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator
Study NCT01938261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Study NCT01938261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45 % saline solution
Description: Placebo
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day
Study NCT00592410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human regular insulin
Description: administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
Study NCT02725294 — intervention group
Intervention type: OTHER
Intervention: This is an observational study without an intervention
Description: Not applicable. This is an observational study without an intervention.
Study NCT06715930 — intervention group
Intervention type: PROCEDURE
Intervention: Interventional treatment
Description: The procedure was performed via the traditional transfemoral arterial approach, under general anesthesia and complete heparin anticoagulation. PEDs were introduced using Marksman or Phenom-27 microcatheters (Medtronic, Irvine, USA), while coils were introduced via Echelon-10 microcatheters (Medtronic, Dublin, Ireland). An appropriate working projection was used to generate three-dimensional rotational angiography. Un-subtracted images were used to verify whether PED was completely deployed and attached to the parent artery. Wall apposition was enhanced using balloon angioplasty if post-deployment imaging indicated inadequate apposition. Overlapping devices were used when a single PED was not enough to cover the aneurysm neck and reconstruct blood flow. Neurointerventionalists with more than 15 years of experience conducted all endovascular procedures. The same dual-antiplatelet therapy was used for 6 months post-procedure, followed by aspirin monotherapy for a minimum of 12 months.
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally once a day
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Administered orally once a day
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01336816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva Silver Wintergreen
Description: Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
Study NCT01336816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Wintergreen
Description: Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
Study NCT04486690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol (propofol to ketamine ratio 1:1)
Description: * Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min
Study NCT04486690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min.
Study NCT01852643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spreader graft
Description: Spreader graft technique is performed by a group of expert surgeons.
Study NCT01852643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral crural overlay
Description: Lateral crural overlay technique is performed by a group of expert surgeons.
Study NCT03827239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity/Moderate Exercise
Description: 3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
Study NCT02751944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM
Description: Dietary supplement for the support of joint health.
Study NCT02751944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04584047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell-based non-invasive prenatal testing
Description: Blood sampling.
Study NCT02311803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preservation of Denonvilliers Fascia
Description: In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
Study NCT02311803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of Denonvilliers Fascia
Description: In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
Study NCT00894777 — intervention group
Intervention type: OTHER
Intervention: Clinical record review
Study NCT00696124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 2 mg
Description: 2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
Study NCT00696124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 4 mg
Description: 4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
Study NCT00696124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 8 mg
Description: 8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
Study NCT00696124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 16 mg
Description: 16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
Study NCT04122378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture will be provided by the licensed acupuncturist using standard methods.
Study NCT00503984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
Study NCT00503984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
Study NCT00503984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
Study NCT00503984 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GADD45α methylation and expression analysis
Description: Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so.
Study NCT00503984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
Study NCT00503984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV
Study NCT00025363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT02934763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
Study NCT02934763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as placebo
Study NCT01769339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole plus Hydrocortisone
Description: Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
Study NCT00969319 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients under daily life treatment receiving Kogenate according to local drug information.
Study NCT02722148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
Description: A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
Study NCT04407078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injectable Product
Description: Sugammadex of 2 mg/kg is injected.
Study NCT04407078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine Injectable Product
Description: Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
Study NCT00025363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT01236560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02268266 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Erigo
Description: The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
Study NCT04461119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evenamide
Description: oral capsules for 4 weeks of treatment
Study NCT04461119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules for 4 weeks of treatment
Study NCT02670902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention-Residential (CTI-R)
Description: CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
Study NCT02670902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Discharge Services-Residential
Description: The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
Study NCT02670902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Discharge Services-Residential
Description: The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
Study NCT01783444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
Study NCT01783444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
Study NCT01783444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Study NCT00025363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00025363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT00025363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally once a day
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally once a day
Study NCT04780958 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.
Description: Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
Study NCT03363217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
Study NCT04173052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testis' shocker
Description: The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
Study NCT02397603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine bupivacaine
Description: perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
Study NCT02397603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine saline
Description: perineural bupivacaine saline mixture in the thoracic paravertebral catheter
Study NCT04196205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T
Description: 1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh
Study NCT02388841 — intervention group
Intervention type: RADIATION
Intervention: Pulmonary embolism
Description: the thrombus were assessed with Computed tomographic pulmonary angiography
Study NCT03563456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured combined exercise
Description: A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
Study NCT03563456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cardiorespiratory exercise
Description: Once per week continuous cardiorespiratory training of moderate intensity
Study NCT01661920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
Study NCT01661920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Those antibiotic duration treatments which are not modified by their doctors.
Study NCT03051841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-581
Description: Intravenously on Days 1, 8 of each 21-day treatment cycle.
Study NCT00879606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-836
Description: In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
Study NCT00879606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
Study NCT05020093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection molding
Description: preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
Study NCT05020093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental packing
Description: Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
Study NCT02833220 — intervention group
Intervention type: DEVICE
Intervention: Single-Pulse Transcranial Magnetic Stimulation
Description: Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
Study NCT04311801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Every patient underwent OCT examination before and after surgery.
Study NCT04156828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV